Myonexus Therapeutics Receives Orphan Drug Designation for MYO-102, an Investigational Gene Therapy for Alpha-sarcoglycanopathy (LGMD2D)

Gene Therapy

Myonexus Therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for MYO-102, a novel gene therapy candidate for alpha-sarcoglycanopathy, also known as Limb Girdle Muscular Dystrophy Type 2D (LGMD2D). Myonexus Therapeutics is a clinical-stage gene therapy company developing first-ever corrective gene therapies for limb girdle muscular dystrophies (LGMD) and has licensed the technology from Nationwide Children’s. Nationwide Children’s holds the Investigational New Drug (IND) application for MYO-102.

Click here to read the complete news release.

News release excerpt provided by Citizen Tribune.

Originally published January 3, 2019.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: